/Companies

23andMe

also invests · investor profileAcquired

Mountain View, US · Delaware corporation · 557 employees on LinkedIn · 30 known investors

Find your way into 23andMe

Sign up to see every warm intro you have to 23andMe

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the 23andMe team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by TTAM Research Institute July 2025 · $305M ($305 million) · source ↗

23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery. The company enables individuals to learn about their genetic traits while contributing to medical research studies that benefit public health.

Founders & leadership

AWAnne Wojcicki
Anne WojcickiFounderBefore starting the consumer genetics company in 2006, she spent roughly a decade as a healthcare investor, working as an analyst at Investor AB, Ardsley Partners, Andor Capital Management and Passport Capital. Her background in biotech and healthcare equities preceded her move into direct-to-consumer genetic testing and research.
LA
Linda AveyFounder
PC
Paul CheungCo-founder
AP
Andrew PageExecutive
KHKathy Hibbs
Kathy HibbsExecutiveKathy Hibbs is an executive with 25 years of experience in life sciences and medical technology, including work in genetics and oncology products. She has served as an independent board member on public and private company boards with expertise in audit, compensation, and governance matters.
PC
Paul CusenzaFounder

Board

EDEsther Dyson
Esther DysonBoard directorFounder of Wellville; chairman of EDventure Holdings
PCPatrick Chung
Patrick ChungBoard directorGeneral Partner at Xfund

Investors · 30

Casdin CapitalreportedNew York

How we know: offering press articles · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: offering press articles · Not right? Tell us

Also in the syndicate · 5

Euclidean CapitalFidelityFidelity ManagementGlaxoSmithKlineWallenberg Foundation

Reported raises · per SEC filings

Form D private placements

$711.6M disclosed across 4 rounds · 2015–2020

▶$82.5MraisedDec 2020 · 23 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anne WojcickiExecutive Officer, Director
  • Kathy HibbsExecutive Officer
  • Steven SchochExecutive Officer
  • Roelof BothaDirector
  • Patrick ChungDirector
  • Richard SchellerDirector
  • Neal MohanDirector
Offering amount
$85M
Amount sold
$82.5M
First sale
Dec 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$300MraisedAug 2018 · 1 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick ChungDirector
  • Anne WojcickiExecutive Officer, Director
  • Steven SchochExecutive Officer
  • Esther DysonDirector
  • Roelof BothaDirector
  • Neal MohanDirector
  • Kathy HibbsExecutive Officer
Offering amount
$300M
Amount sold
$300M
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$250MraisedSep 2017 · 31 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Kathy L. HibbsExecutive Officer
  • Neal MohanDirector
  • Dean SchornoExecutive Officer
  • Roelof BothaDirector
  • Anne WojcickiExecutive Officer, Director
  • Esther DysonDirector
  • Patrick S. ChungDirector
Offering amount
$250M
Amount sold
$250M
Finders' fees
$7.5M
Placement agents
Allen & Company LLC
First sale
Aug 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$79.1MraisedJul 2015 · 15 investors · Other Technology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anne WojcickiExecutive Officer, Director
  • Andrew PageExecutive Officer, Director
  • Esther DysonDirector
  • Kathy HibbsExecutive Officer
  • Patrick ChungDirector
Offering amount
$150M
Amount sold
$79.1M
First sale
Jun 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

6 people who came through 23andMe went on to found or lead other companies.

Related companies · 1

Companies working in the same space as 23andMe.

Acquisitions · 1

Early investors' stakes continue via these deals
Lemonaid

Lemonaid Health is a telehealth company that lets patients access medical care and treatment online from home, including services like contraceptive pill prescriptions and UTI treatment. It serves patients primarily in the United States, with a later launch in the UK.

In the news

Frequently asked questions

What does 23andMe do?
23andMe operates a research platform that collects genetic data from millions of users to advance genomic research and health discovery. The company enables individuals to learn about their genetic traits while contributing to medical research studies that benefit public health.
Who founded 23andMe?
23andMe was founded by Anne Wojcicki, Linda Avey, Paul Cheung.
Who are 23andMe's investors?
23andMe's investors include Adam Nash, Allied Venture Partners, Bright Success Capital, Civilization Ventures Management, Llc, EQUIAM, Firebolt Ventures Management Company, Llc, G Squared, GV (Google Ventures) and 17 more.
How much funding has 23andMe raised?
23andMe has disclosed $711.6M raised across 4 rounds.
Where is 23andMe headquartered?
23andMe is headquartered in Mountain View, US.